awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47164735-4D106D5A-D148-4F06-98B2-0233F4F5A351
Q47164735-4D106D5A-D148-4F06-98B2-0233F4F5A351
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47164735-4D106D5A-D148-4F06-98B2-0233F4F5A351
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
P2860
Q47164735-4D106D5A-D148-4F06-98B2-0233F4F5A351
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47164735-4D106D5A-D148-4F06-98B2-0233F4F5A351
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6b8edce1e3ebdb0faf61d603c3939ebe5d7b0c46
P2860
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res